FDA Accepts Supplemental NDA for Terlivaz by Mallinckrodt
The FDA has accepted a supplemental NDA for Terlivaz (terlipressin acetate) submitted by Mallinckrodt.
Asset
Mallinckrodt
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's acceptance of the supplemental NDA for Terlivaz is a significant regulatory milestone that could strengthen Mallinckrodt's competitive position in the hepatology market. This development necessitates close monitoring of competitive responses and market dynamics as other companies may react to this advancement.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for further updates on the approval timeline and any competitive reactions from other companies in the space.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.